Recombinant PDCD1 (Pembrolizumab Biosimilar) antibody

Catalog No. ABIN7487773

The Mammalian Cells Monoclonal anti-PDCD1 (Pembrolizumab Biosimilar) antibody has been validated for ELISA. It is suitable to detect PDCD1 (Pembrolizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant PDCD1 (Pembrolizumab Biosimilar) antibody (ABIN7487773)

Target: PDCD1 (Pembrolizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This PDCD1 (Pembrolizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-PDCD1 (Pembrolizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Pembrolizumab Biosimilar - Anti-PD1 mAb

Characteristics: Antibody Type: IgG4

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG4

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: 4 °C,-20 °C

Storage Comment: 4°C for short term, -20°C for long term

Target Details for PDCD1 (Pembrolizumab Biosimilar)

Target: PDCD1 (Pembrolizumab Biosimilar)

Target Type: Biosimilar

Background: Pembrolizumab
Pembrolizumab is a humanized (from mouse) monoclonal antibody that binds to, and blocks PD-1 located on lymphocytes. It is an anticancer medication used in the treatment of melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial cancer (cancer of the bladder and urinary tract) and renal cell carcinoma (kidney cancer).